Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention
酒精滥用、肠道微生物失调和 PrEP 护理连续体:SBIRT 干预的应用和功效
基本信息
- 批准号:10701829
- 负责人:
- 金额:$ 69.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-10 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAddressAdherenceAdverse eventAffectAlcohol abuseAlcohol consumptionAlcoholsAmbulatory Care FacilitiesBehavioralBiologicalCaringClinicClinicalClinical ResearchContinuity of Patient CareDataData CollectionDecision MakingEarly InterventionEarly treatmentEffectivenessEventExhibitsFeedbackGoalsHIVHIV SeronegativityHealthHealthcareIndividualInjury to KidneyInternal MedicineInterventionInterviewIntestinal permeabilityKidney DiseasesLiver diseasesLongitudinal StudiesLongitudinal cohort studyMaintenanceMovementNauseaOutcomeParticipantPathogenicityPatternPersonsPharmaceutical PreparationsPopulationProcessPublic HealthQualitative MethodsRandomizedRandomized, Controlled TrialsReactionRegimenResearchResearch PersonnelRiskStructureSubgroupTestingTimeTreatment EffectivenessTriageUniversitiesVomitingalcohol measurementalcohol misusealcohol risk reductionappetite lossattenuationdysbiosiseffectiveness testingefficacy evaluationenteric dysbiosisexperiencegastrointestinalgut dysbiosisgut microbiomegut-liver axisimprovedintestinal homeostasisliver functionliver injurymicrobialmicrobial communitypre-exposure prophylaxispreventrecruitreduced alcohol usescreeningscreening, brief intervention, referral, and treatmentside effectsystemic inflammatory responsetransmission processtreatment as usualtreatment programuptake
项目摘要
Pre-exposure prophylaxis (PrEP), a medication regimen to reduce HIV transmission risk among HIV negative
individuals, has utility in helping to reach national HIV prevention goals. However, clinical side effects,
particularly those impacting gastrointestinal (GI) (nausea, vomiting, loss of appetite), hepatic and renal injury
outcomes may inhibit PrEP persistence. Importantly, alcohol use which is frequent in PrEP users may interact
with PrEP and exacerbate PrEP-associated adverse GI effects and consequently affect PrEP persistence.
Recent data implicates that these side effects are likely associated with changes in the gut microbiome
(dysbiosis). Despite the important ramifications that PrEP, alcohol, and their combined use may have on the
gut dysbiosis and subsequent PrEP continuance, there is little research to elucidate this interaction and few
attempts to address it. Moreover, there is little research exploring decision-making processes regarding alcohol
and PrEP utilization and adherence among PrEP users. To address these gaps in research, this study will
employ the following aims. Aim 1: Qualitatively explore mechanisms by which alcohol use impacts
movement through the PrEP continuum and understand how an early intervention and treatment
approach impacts alcohol use and PrEP adherence. Aim 2: Investigate the effectiveness of the SBIRT
intervention in preventing hazardous alcohol use and its impact on gut dysbiosis in PrEP users. Within
this longitudinal cohort study, we will identify alcohol impacted participants, with patterns of use
ranging from episodic to long-term (engaging in risky or hazardous use). Aim 3: To determine
alterations in the gut microbiome (dysbiosis), intestinal homeostasis, systemic inflammation, and
markers of liver disease associated with hazardous alcohol use among PrEP users. Recruiting from local
PrEP clinics, we will determine alterations in the gut microbiome, intestinal homeostasis, systemic inflammation
and markers of liver disease associated with alcohol and PrEP use. We will also execute a randomized control
trial among PrEP users demonstrating heightened alcohol use to test the effectiveness of the Screening, Brief
Intervention, & Referral to Treatment (SBIRT) intervention to reduce alcohol use and examine subsequent
impact on the gut microbiome compared to individuals receiving treatment as usual and PrEP users not
demonstrating elevated alcohol use. Finally, we will employ qualitative methods (in-depth interviews) and
analysis to understand decision-making factors influencing PrEP adherence and alcohol use over time. Priority
populations, including those engaging in alcohol use, need to increase engagement in the PrEP Care
Continuum to optimize HIV prevention. Clinical research has yet to focus on interactions between PrEP,
alcohol use and GI adverse events. This study may have important implications for mitigating a salient
challenge to PrEP adherence and persistence (side-effects) and elucidating, from clinical and public
health standpoints, factors promoting maintenance in the PrEP care continuum.
暴露前预防(PrEP),一种在HIV阴性人群中减少HIV传播风险的药物治疗方案
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A conceptual analysis of SBIRT implementation alongside the continuum of PrEP awareness: domains of fit and feasibility.
- DOI:10.3389/fpubh.2023.1310388
- 发表时间:2023
- 期刊:
- 影响因子:5.2
- 作者:Harris, Lesley M.;Kerr, Jelani C.;Skidmore, Blake D.;Ghare, Smita;Reyes-Vega, Andrea;Remenik-Zarauz, Vania;Samanapally, Harideep;Anwar, Rana Usman;Rijal, Rishikesh;Bryant, Kendall;Hall, Martin T.;Barve, Shirish
- 通讯作者:Barve, Shirish
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHIRISH S BARVE其他文献
SHIRISH S BARVE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHIRISH S BARVE', 18)}}的其他基金
Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention
酒精滥用、肠道微生物失调和 PrEP 护理连续体:SBIRT 干预的应用和功效
- 批准号:
10542284 - 财政年份:2022
- 资助金额:
$ 69.01万 - 项目类别:
Microbiome, Metabolites, and Alcohol in HIV to Reduce CVD (Supplement)
HIV 中的微生物组、代谢物和酒精可减少 CVD(补充)
- 批准号:
10672807 - 财政年份:2021
- 资助金额:
$ 69.01万 - 项目类别:
Microbiome, Metabolites, and Alcohol in HIV to Reduce CVD (META HIV CVD)
HIV 中的微生物组、代谢物和酒精可减少 CVD(META HIV CVD)
- 批准号:
10685506 - 财政年份:2021
- 资助金额:
$ 69.01万 - 项目类别:
Microbiome, Metabolites, and Alcohol in HIV to Reduce CVD (Supplement)
HIV 中的微生物组、代谢物和酒精可减少 CVD(补充)
- 批准号:
10846342 - 财政年份:2021
- 资助金额:
$ 69.01万 - 项目类别:
Microbiome, Metabolites, and Alcohol in HIV to Reduce CVD (META HIV CVD)
HIV 中的微生物组、代谢物和酒精可减少 CVD(META HIV CVD)
- 批准号:
10304046 - 财政年份:2021
- 资助金额:
$ 69.01万 - 项目类别:
Role of Gut Microbial Dysbiosis and Aging on HIV-associated neurocognitive and brain dysfunction
肠道微生物失调和衰老对 HIV 相关神经认知和脑功能障碍的作用
- 批准号:
10410552 - 财政年份:2018
- 资助金额:
$ 69.01万 - 项目类别:
Role of Gut Microbial Dysbiosis and Aging on HIV-associated neurocognitive and brain dysfunction
肠道微生物失调和衰老对 HIV 相关神经认知和脑功能障碍的作用
- 批准号:
10242623 - 财政年份:2018
- 资助金额:
$ 69.01万 - 项目类别:
1/2 Alcohol Associated Comorbidities and Microbiome Evaluation in HIV (ACME HIV)
1/2 HIV 酒精相关合并症和微生物组评估 (ACME HIV)
- 批准号:
9408280 - 财政年份:2017
- 资助金额:
$ 69.01万 - 项目类别:
相似海外基金
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 69.01万 - 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
- 批准号:
10738120 - 财政年份:2023
- 资助金额:
$ 69.01万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10526768 - 财政年份:2022
- 资助金额:
$ 69.01万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10701072 - 财政年份:2022
- 资助金额:
$ 69.01万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10679092 - 财政年份:2021
- 资助金额:
$ 69.01万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10432133 - 财政年份:2021
- 资助金额:
$ 69.01万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10327065 - 财政年份:2021
- 资助金额:
$ 69.01万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10377366 - 财政年份:2019
- 资助金额:
$ 69.01万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10574496 - 财政年份:2019
- 资助金额:
$ 69.01万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 69.01万 - 项目类别: